Drug Profile
Anti-CD3-anti-HER2/neu-activated T cells - TransTarget
Alternative Names: Anti-CD3 activated T cells targeted with anti-CD3-anti-HER2 bispecific antibody; ATC targeted with HER2Bi; HER2Bi-armed ATCLatest Information Update: 10 Jun 2019
Price :
$50
*
At a glance
- Originator TransTarget
- Developer Barbara Ann Karmanos Cancer Institute; National Cancer Institute (USA)
- Class Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Breast cancer